Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2024Diabetes

735-P: Association between Glucagon-Like Peptide 1 Receptor Agonists and Risk of Depression in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

Ying Lü
Ying LüStanford UniversityHTHUILIN TANGUniversity of PennsylvaniaWDWilliam T. DonahooDiabetes Australia

Discussion

Loading...

Member takes

Implication

Population-based cohort study finds lower depression risk with GLP-1 receptor agonists in older adults with type 2 diabetes, suggesting potential antidepressant benefits.

Key Points

  • A decreased risk of incident depression occurred among older adults receiving glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase 4 inhibitors.
  • A hazard ratio of 0.81 reflected a significantly reduced risk of depression among 25,824 Medicare beneficiaries with type 2 diabetes followed during the study period.
  • Propensity score matching and Cox proportional hazards regression in Medicare claims data showed reduced depression, highlighting potential psychiatric benefits in diabetes.

Cite This Study

Lü et al. (2024) studied this question.

synapsesocial.com/papers/68e64c51b6db6435875dd4abhttps://doi.org/10.2337/db24-735-p
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of Depression With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Compared to Other Antidiabetic Medications in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis2026
  2. 2Risk of depression with <scp>GLP</scp>‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study2025 · 13 citations
  3. 3232-OR: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-Harm in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study2024
  4. 4Association Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study2026
  5. 5750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes2024